Anti-TDP43 Rabbit Monoclonal Antibody

Overview

This product is an anti-TARDBP antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 26T75; isotype IgG; reactivity: Human,Mouse,Rat. Reported application contexts include WB, IHC, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-TDP43 Rabbit Monoclonal Antibody catalog # M01001-2. Tested in WB, IHC, ICC, IF, Flow Cytometry applications. This antibody reacts with Human, Mouse, Rat.

Key elements and design rationale

• Target: TARDBP (TAR DNA-binding protein 43).
• Antibody format: Monoclonal; clone 26T75; isotype IgG.
• Host: Rabbit.
• Species reactivity: Human,Mouse,Rat (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

TARDBP (protein: Glycogen synthase kinase-3 beta (gsk3b)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): DNA and RNA-binding protein which regulates transcription and splicing. Involved in the regulation of CFTR splicing. It promotes CFTR exon 9 skipping by binding to the UG repeated motifs in the polymorphic region near the 3'-splice site of this exon. The resulting aberrant splicing is associated with pathological features typical of cystic fibrosis. May also be involved in microRNA biogenesis, apoptosis and cell division. Can repress HIV-1 transcription by binding to the HIV-1 long terminal repeat. Stabilizes the low molecular weight neurofilament (NFL) mRNA through a interaction with the 3' UTR. . Reported cellular localization context: Nucleus . In patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis, it is absent from the nucleus of affected neurons but it is the primary component of cytoplasmic ubiquitin-positive inclusion bodies. Tissue expression notes (as provided): Ubiquitously expressed. In particular, expression is high in pancreas, placenta, lung, genital tract and spleen.

Research relevance and current trends

• Research context keywords from the source record include: Alzheimer's Disease,Cancer,Cancer Metabolism,Cardiovascular,Energy Transfer Pathways,Fatty Acid Oxidation,Fatty Acids,Integration Of Energy,Integration Of Energy Metabolism,Lipid and Lipoprotein Metabolism,Lipids/Lipoproteins,Metabolic Signaling Pathway,Metabolic Signaling Pathways,Metabolism,Metabolism Processes,Neurodegenerative Disease,Neurology Process,Neuroscience,Pathways and Processes,Protein Phosphorylation,Redox Metabolism,Response To Hypoxia,Ser/Thr Kinases,Signal Transduction.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunohistochemistry (IHC): evaluate spatial distribution of target-positive staining in tissue architecture.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.

Workflow ideas (metafield): Validate TARDBP antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect TARDBP expression by Western blot in cell or tissue lysates, Detect TARDBP in FFPE tissue sections by immunohistochemistry, Localize TARDBP by immunofluorescence/immunocytochemistry in cultured cells, Quantify TARDBP-positive cells by flow cytometry in single-cell suspensions

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 45 kDa; calculated MW: 44740 MW).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 45 kDa
• Cellular localization (provided): Nucleus . In patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis, it is absent from the nucleus of affected neurons but it is the primary component of cytoplasmic ubiquitin-positive inclusion bodies.
• Tissue details (provided): Ubiquitously expressed. In particular, expression is high in pancreas, placenta, lung, genital tract and spleen.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.